prikaz prve stranice dokumenta Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor
  Download
PDF 350.84 KB
Scientific paper - Original scientific paper
Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor
Medical Science Monitor, 19 (2013); 845-851. https://doi.org/10.12659/MSM.889554
Flego, Veljko; Ristić, Smiljana; Dević Pavlić, Sanja; Matanić Lender, Dubravka; Bulat-Kardum, Ljiljana; Radojčić Badovinac, Anđelka

Cite this document

Flego, V., Ristić, S., Dević Pavlić, S., Matanić Lender, D., Bulat Kardum, Lj. & Radojčić Badovinac, A. (2013). Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor. Medical Science Monitor, 19., 845-851. doi: 10.12659/MSM.889554

Flego, Veljko, et al. "Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor." Medical Science Monitor, vol. 19, 2013, pp. 845-851. https://doi.org/10.12659/MSM.889554

Flego, Veljko, Smiljana Ristić, Sanja Dević Pavlić, Dubravka Matanić Lender, Ljiljana Bulat Kardum and Anđelka Radojčić Badovinac. "Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor." Medical Science Monitor 19 (2013): 845-851. https://doi.org/10.12659/MSM.889554

Flego, V., et al. (2013) 'Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor', Medical Science Monitor, 19, pp. 845-851. doi: 10.12659/MSM.889554

Flego V, Ristić S, Dević Pavlić S, Matanić Lender D, Bulat Kardum Lj, Radojčić Badovinac A. Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor. Medical Science Monitor [Internet]. 2013 [cited 2024 November 28];19:845-851. doi: 10.12659/MSM.889554

V. Flego, S. Ristić, S. Dević Pavlić, D. Matanić Lender, Lj. Bulat Kardum and A. Radojčić Badovinac, "Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor", Medical Science Monitor, vol. 19, pp. 845-851, 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:614906. [Accessed: 28 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor
AuthorVeljko Flego
AuthorSmiljana Ristić
AuthorSanja Dević Pavlić
AuthorDubravka Matanić Lender
AuthorLjiljana Bulat-Kardum
AuthorAnđelka Radojčić Badovinac
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Human Genetics, Genomics and Proteomics
Abstract (english)
Lung cancer is the most common second primary cancer. We investigated whether the TNF-a-308 and TNF-a-238 polymorphisms were associated with the susceptibility and severity of lung cancer as the second primary cancer (LC2). Material/Methods: This study included 104 patients from the group LC2. The control subjects included 2 groups. The first control group (LC1) comprised 201 unrelated patients with lung cancer as a first primary cancer. The second control group (HC) comprised 230 healthy blood donors, matched for sex and age to the study group. Results: The frequencies of the TNF-a-238 polymorphism GG genotype and the G allele were higher in the LC2 group than in the LC1 group, but the differences did not reach significance (p=0.054 and p=0.057, respectively). Similar differences were found in the TNF-a-238 polymorphism GG genotype and G allele between the LC2 group and the HC group (p=0.054 and p=0.057, respectively). In terms of the different types of lung cancer, patients with a second primary NSCLC (non-small cell lung cancer) more frequently had TNF-a-238 polymorphism GG genotypes and G alleles than patients with a first primary NSCLC (the differences approached statistical significance: p=0.060, p=0.064, respectively). All (100%) patients of group LC2 (n=104) had the GG genotype and the G allele. GG genotype was exclusive and no A allele was found in group LC2. Conclusions: TNF-a-238 polymorphism GG genotype and the G allele could have a promotional effect on the development of NSCLC in the group of patients with LC2.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleMedical Science Monitor
Numberingvol. 19, pp. 845-851
e-ISSN1643-3750
DOIhttps://doi.org/10.12659/MSM.889554
URN:NBNurn:nbn:hr:184:614906
Online first2013
Document URLhttps://www.medscimonit.com/download/index/idArt/889554
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2017-08-02 09:14:00